alexa Plasma Metabolomic Signature Of Novel Signal Transduction Inhibitors: From Preclinical Identification To Clinical Validation
ISSN: 2153-0769

Metabolomics:Open Access
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference and Exhibition on Metabolomics & Systems Biology
March 24-26, 2014 Hilton San Antonio Airport, San Antonio, USA

Florence I. Raynaud
ScientificTracks Abstracts: Metabolomics
DOI: 10.4172/2153-0769.S1.024
Abstract
Early clinical studies of novel agents evaluate both pharmacokinetic and pharmacodynamic profiles. In preclinical oncology studies, the biomarker of interest can be measured in tumor material but in clinical development, not all tumors are accessible and patients cannot be regularly biopsied. Therefore, identification of circulating biomarkers is extremely useful in assisting clinical development of novel oncology products. We have been using non-targeted followed by targeted LCMS to evaluate if plasma metabolomics can be used to monitor the effect of novel signal transduction inhibitors. We show that significant differences in the plasma metabolome of genetically engineered PTEN+/- mice when comparing with littermate controls and in mice bearing PTEN-/- human tumor xenografts compared with non-tumor bearing animals. This signature can be reversed by a PI3K inhibitor. The plasma metabolomic signature of nude mice bearing a B-RAF of K-RAS mutant tumor xenograft is different to that observed in PTEN-/- animals and can be reversed using a MEK inhibitor in mice bearing human tumour xenograft. The metabolic signatures include amino acids, carnitine derivatives and lipids some of which are affected by time of day and food intake. Therefore, the effect of food and sampling time need to be incorporated in the analysis. Despite these variations, the preclinical signatures identified following a PI3K or MEK inhibitor can be observed in patients following treatment with a pan class I PI3K inhibitor and a MEK inhibitor. These data suggest that plasma metabolomic is a valid strategy to monitor the pharmacodynamic development of novel anticancer agents.
Biography
Florence I. Raynaud completed her Ph.D. at the University of Strasbourg, France where she carried out her first post-doctoral position. She is currently leader of the drug metabolism and pharmacokinetics team at the Institute of Cancer Research where she is involved in the preclinical and clinical development of novel anticancer agents. She has been involved in the preclinical development of 20 novel agents that have reached clinical trials. These include abiraterone which has been registered for advanced prostate cancer. She is the author of over 100 publications and is on the editorial board of Clinical Cancer Pharmacology.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords